2009
Acute phosphate nephropathy
Markowitz GS, Perazella MA. Acute phosphate nephropathy. Kidney International 2009, 76: 1027-1034. PMID: 19675530, DOI: 10.1038/ki.2009.308.Peer-Reviewed Original ResearchConceptsAcute phosphate nephropathyAcute kidney injuryChronic kidney diseasePhosphate nephropathySubsequent chronic renal failureChronic tubular injuryAngiotensin receptor blockersChronic renal failureHigh-risk patientsRenal biopsy findingsClinical-pathological entityAggressive hydrationKidney injuryReceptor blockersBiopsy findingsRenal failureTubular injuryKidney diseasePathological entityRisk factorsFemale genderDistal tubulesEpidemiologic studiesDistal nephronEnzyme inhibitors
2004
Fellows’ Forum in Dialysis. Depression: A Common but Underrecognized Condition Associated with End‐Stage Renal Disease
Perazella M, Wang P, Watnick S. Fellows’ Forum in Dialysis. Depression: A Common but Underrecognized Condition Associated with End‐Stage Renal Disease. Seminars In Dialysis 2004, 17: 237-241. PMID: 15144552, DOI: 10.1111/j.0894-0959.2004.17313.x.Peer-Reviewed Original ResearchUse of Low Molecular Weight Heparins and Glycoprotein IIb/IIIa Inhibitors in Patients with Chronic Kidney Disease
Perazella M, Mosenkis A, Berns J. Use of Low Molecular Weight Heparins and Glycoprotein IIb/IIIa Inhibitors in Patients with Chronic Kidney Disease. Seminars In Dialysis 2004, 17: 411-416. PMID: 15461751, DOI: 10.1111/j.0894-0959.2004.17351.x.Peer-Reviewed Original ResearchMeSH KeywordsAgedAngina, UnstableDiabetes Mellitus, Type 2Diabetic NephropathiesDose-Response Relationship, DrugDrug Administration ScheduleDrug Therapy, CombinationFollow-Up StudiesHeparin, Low-Molecular-WeightHumansKidney Failure, ChronicMalePlatelet Aggregation InhibitorsPlatelet Glycoprotein GPIIb-IIIa ComplexRisk AssessmentTreatment OutcomeConceptsLow molecular weight heparinIIb/IIIa inhibitorsChronic kidney diseaseAcute coronary syndromeEnd-stage renal diseaseMolecular weight heparinWeight heparinKidney diseaseGlycoprotein IIb/IIIa inhibitorsGP IIb/IIIa inhibitorsSafety of LMWHLarge prospective trialsMajor clinical trialsCardiac causesCoronary syndromeAppropriate dosingProspective trialRenal diseaseKidney functionAggressive interventionClinical benefitClinical trialsPatientsSignificant impairmentDiseaseIntravenous Iron and the Risk of Infection in End‐Stage Renal Disease Patients
Perazella M, Brewster U, Perazella M. Intravenous Iron and the Risk of Infection in End‐Stage Renal Disease Patients. Seminars In Dialysis 2004, 17: 57-60. PMID: 14717813, DOI: 10.1111/j.1525-139x.2004.17115.x.BooksMeSH KeywordsBacteriaBacterial InfectionsFemaleHumansInfusions, IntravenousIronKidney Failure, ChronicMiddle AgedRisk FactorsStaphylococcal InfectionsConceptsInnate immune responseRisk of infectionIntravenous ironEnd-stage renal disease patientsHost innate immune responseRenal disease patientsIron-deficient patientsAdministration of ironOral ironIron therapyMost patientsHemodialysis patientsActive infectionDisease patientsIron preparationsIron overloadAllergic reactionsClinical studiesImmune responsePatientsBacterial infectionsIron deficiencyInfectionRiskBacterial growth
2003
Nephrogenic Fibrosing Dermopathy: An Unusual Skin Condition Associated with Kidney Disease
Perazella MA, Ishibe S, Perazella MA, Reilly RF. Nephrogenic Fibrosing Dermopathy: An Unusual Skin Condition Associated with Kidney Disease. Seminars In Dialysis 2003, 16: 276-280. PMID: 12753692, DOI: 10.1046/j.1525-139x.2003.16053.x.BooksConceptsCommon patient complaintLong-term hemodialysisNephrogenic fibrosing dermopathyCorticosteroid therapyInflammatory cellsKidney diseasePatient complaintsMucin depositsSkin biopsiesSpindle cellsSkin disordersFibroblast-type cellsReticular dermisCollagen bundlesInternal organsIncreased numberHemodialysisPatientsSclerodermaDisordersCellsDysesthesiaPruritusBiopsyDysfunction
2001
Pharmacologic options available to treat symptomatic intradialytic hypotension
Perazella M. Pharmacologic options available to treat symptomatic intradialytic hypotension. American Journal Of Kidney Diseases 2001, 38: s26-s36. PMID: 11602458, DOI: 10.1053/ajkd.2001.28092.Peer-Reviewed Original ResearchConceptsSymptomatic intradialytic hypotensionIntradialytic hypotensionHigh-risk patientsLower blood pressurePharmacologic optionsPharmacologic therapyBlood pressurePatient factorsAvailable therapiesPharmacologic interventionsHypotensionTherapyTreatmentInitial approachMidodrineNephrologistsPatientsSertralineTreatment of Severe Intradialytic Hypotension With the Addition of High Dialysate Calcium Concentration to Midodrine and/or Cool Dialysate
Alappan R, Cruz D, Abu-Alfa A, Mahnensmith R, Perazella M. Treatment of Severe Intradialytic Hypotension With the Addition of High Dialysate Calcium Concentration to Midodrine and/or Cool Dialysate. American Journal Of Kidney Diseases 2001, 37: 294-299. PMID: 11157369, DOI: 10.1053/ajkd.2001.21292.Peer-Reviewed Original ResearchMeSH KeywordsBlood PressureCalciumFemaleHemodialysis SolutionsHumansHypotensionKidney Failure, ChronicMaleMiddle AgedMidodrineRenal DialysisTemperatureConceptsHigh dialysate calcium concentrationSevere intradialytic hypotensionDialysate calcium concentrationIntradialytic hypotensionBlood pressureEnd-stage renal disease populationCalcium concentrationLow dialysate calciumSeverity of hypotensionMean arterial pressurePeripheral vascular resistanceIntradialytic blood pressureRenal disease populationProspective crossover studyTreatment of patientsMultiple pathogenic factorsType of therapyDialysate calciumHemodynamic instabilityVascular resistanceHemodynamic stabilityArterial pressureCrossover studyCardiac outputCool dialysate
2000
Ace inhibitors do not induce recombinant human erythropoietin resistance in hemodialysis patients
Abu-Alfa A, Cruz D, Perazella M, Mahnensmith R, Simon D, Bia M. Ace inhibitors do not induce recombinant human erythropoietin resistance in hemodialysis patients. American Journal Of Kidney Diseases 2000, 35: 1076-1082. PMID: 10845820, DOI: 10.1016/s0272-6386(00)70043-6.Peer-Reviewed Original ResearchMeSH KeywordsAnemiaAngiotensin-Converting Enzyme InhibitorsAntihypertensive AgentsBlood PressureBlood TransfusionCross-Over StudiesDiabetes ComplicationsDrug ResistanceEpoetin AlfaErythropoietinFemaleFollow-Up StudiesHematinicsHematocritHospitalizationHumansInfectionsKidney Failure, ChronicLisinoprilMaleMiddle AgedProspective StudiesRecombinant ProteinsRenal DialysisTime FactorsConceptsACE inhibitor therapyACE inhibitorsHemodialysis patientsRHuEPO resistanceInhibitor therapyRecombinant human erythropoietin resistanceRecombinant human erythropoietin (rHuEPO) requirementsBlood pressure controlChronic renal failureDuration of infectionRHuEPO doseTransfusion requirementsErythropoietin resistanceRenal failureDialysis patientsHospitalization daysLaboratory parametersRHuEPO dosesAntihypertensive agentsCrossover studyErythropoietin requirementsInclusion criteriaPatientsAverage ageEnzyme inhibitors
1999
Midodrine and cool dialysate are effective therapies for symptomatic intradialytic hypotension
Cruz D, Mahnensmith R, Brickel H, Perazella M. Midodrine and cool dialysate are effective therapies for symptomatic intradialytic hypotension. American Journal Of Kidney Diseases 1999, 33: 920-926. PMID: 10213650, DOI: 10.1016/s0272-6386(99)70427-0.Peer-Reviewed Original ResearchConceptsSymptomatic intradialytic hypotensionPost-HD blood pressuresIntradialytic blood pressureIntradialytic hypotensionBlood pressureEffective therapyLaboratory valuesCombination therapy phaseConsecutive HD treatmentsProspective crossover studyBlood pressure measurementsKt/VVolume of salineControl phaseAlpha1 agonistHypotensive symptomsMorbid complicationCrossover studyUseful therapyProspective studyNursing interventionsHD treatmentMidodrineTreatment phaseTherapy phase
1998
Indinavir nephropathy in an AIDS patient with renal insufficiency and pyuria.
Perazella M, Kashgarian M, Cooney E. Indinavir nephropathy in an AIDS patient with renal insufficiency and pyuria. Clinical Nephrology 1998, 50: 194-6. PMID: 9776425.Peer-Reviewed Original ResearchConceptsRenal biopsy findingsRenal insufficiencyBiopsy findingsMild renal insufficiencyAcute renal failureIndinavir crystalsIndinavir therapyRenal failureAntiretroviral agentsUrinary obstructionAIDS patientsCellular castsPatientsPyuriaInsufficiencyRecent reportsSmall percentDiscontinuationNephropathyMedicationsSecond caseDiuresisNephrolithiasisIndinavirObstructionMidodrine is effective and safe therapy for intradialytic hypotension over 8 months of follow-up.
Cruz D, Mahnensmith R, Brickel H, Perazella M. Midodrine is effective and safe therapy for intradialytic hypotension over 8 months of follow-up. Clinical Nephrology 1998, 50: 101-7. PMID: 9725781.Peer-Reviewed Original ResearchConceptsSymptomatic intradialytic hypotensionIntradialytic hypotensionMidodrine therapyHD sessionSafe therapyEnd-stage renal disease patientsStage renal disease patientsAlpha-1 adrenergic agonistMean ultrafiltration volumeSignificant causative roleRenal disease patientsTreatment-related factorsPatient-specific factorsMost therapeutic interventionsKt/VHypotensive symptomsBlood pressureHemodialysis patientsHD patientsDisease patientsSubjective improvementAdverse reactionsFrustrating complicationMean albuminSafe treatment
1997
Intradialytic hypotension: Is midodrine beneficial in symptomatic hemodialysis patients?
Cruz D, Mahnensmith R, Perazella M. Intradialytic hypotension: Is midodrine beneficial in symptomatic hemodialysis patients? American Journal Of Kidney Diseases 1997, 30: 772-779. PMID: 9398120, DOI: 10.1016/s0272-6386(97)90081-0.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, OralAdrenergic alpha-AgonistsAgedAged, 80 and overBlood PressureDiastoleDizzinessFatigueFemaleFollow-Up StudiesHumansHypotensionKidney Failure, ChronicLongitudinal StudiesMaleMiddle AgedMidodrineMuscle CrampMuscle WeaknessParesthesiaProspective StudiesPulseRenal DialysisRisk FactorsSafetyScalpSystoleConceptsDiastolic blood pressureSystolic blood pressureBlood pressureMidodrine therapyArterial pressureHemodialysis patientsIntradialytic hypotensionPulse rateEnd-stage renal disease patientsIntradialytic systolic blood pressureEfficacy of midodrineSymptomatic hemodialysis patientsNeurogenic orthostatic hypotensionMean arterial pressureRenal disease patientsAdequate patient numbersBlood pressure measurementsAlpha-adrenergic agonist activityConsecutive dialysis sessionsAutonomic dysfunctionDialysis hypotensionOral agentsOrthostatic hypotensionSymptomatic hypotensionProspective trialBiochemical aberrations in a dialysis patient following parathyroidectomy
Cruz D, Perazella M. Biochemical aberrations in a dialysis patient following parathyroidectomy. American Journal Of Kidney Diseases 1997, 29: 759-768. PMID: 9159312, DOI: 10.1016/s0272-6386(97)90131-1.Peer-Reviewed Original ResearchConceptsEnd-stage renal diseaseSevere secondary hyperparathyroidismCalcitriol therapySurgical parathyroidectomyIntensive regimenSecondary hyperparathyroidismElectrolyte abnormalitiesRenal osteodystrophySevere hypocalcemiaDialysis patientsRenal diseasePostoperative managementHigh riskParathyroidectomyPatientsBiochemical aberrationsCommon problemHyperparathyroidismHypocalcemiaHyperkalemiaHypophosphatemiaOsteodystrophyRegimenAberrationsTherapy
1993
Renal Failure and Severe Hypokalemia Associated With Acute Myelomonocytic Leukemia
Perazella M, Eisen R, Frederick W, Brown E. Renal Failure and Severe Hypokalemia Associated With Acute Myelomonocytic Leukemia. American Journal Of Kidney Diseases 1993, 22: 462-467. PMID: 8372846, DOI: 10.1016/s0272-6386(12)70154-3.Peer-Reviewed Original ResearchMeSH KeywordsAgedHumansHypokalemiaImmunoenzyme TechniquesKidney Failure, ChronicKidney GlomerulusLeukemia, Myelomonocytic, AcuteMaleConceptsAcute myelomonocytic leukemiaRenal failureMyelomonocytic leukemiaRenal parenchymal infiltrationRenal tubular injuryHypokalemia AssociatedInappropriate kaliuresisMicrovascular insufficiencyRenal insufficiencySevere hypokalemiaTubular injuryParenchymal infiltrationSetting of leukemiaBlast cellsLeukemiaMetabolic perturbationsHypokalemiaVariety of mechanismsInsufficiencyFailureLeukostasisKaliuresisEtiologyInjury